Medical Research Projects Nutraceutical product destined to VHC viral chronic hepatitis patients

Nutraceutical product destined to VHC viral chronic hepatitis patients

  • Project :
    • Nutraceutical product destined to VHC viral chronic hepatitis patients, obtained through biotechnological methods
  • Coordinating Institution :
    • The Applicative Research and Investment Company, Bucharest
  • Associated Organisations :
    • "Dr Victor Babes" Clinical Hospital for Infectious and Tropical Diseases, Bucharest
    • "Dr. Victor Babes" Foundation, Bucharest
    • "Faves Biovital" Laboratory, Orastie
  • The running period :
    • October 2006 - September 2008
  • Project Manager :
    • Prof. Dr. Ghe. Mencinicopschi
  • "Dr. Victor Babes" Fundation Coordinator :
    • Dr. Alma Tudor
  • Financed by :
    • Minister of Education and Research; CEEX 2006 (Agral Program)
  • About project :
    • This project's target is to elaborate a nutraceutical product, biologically natural active, with a controlled content of hydro carbonates, proteins, lipids, trace elements, vitamins. This nutraceutical product can be used in the complementary nutrition of the patients with Chronic Viral Hepatitis, associated to the basis treatment.
    • The nutraceutical products represent a new food generation with a high bio reserve of components that give an optimum effect in severe infections, but can also constitute the basis for a preventive strategy.
    • The term of "nutraceutical product" was given in Japan by "Japanese Food for Specified Health USC" (FOSHU).
    • The nutraceutical products bring benefits to health without being considered "medicines". It was demonstrated that these products influence for the better one or more than one target functions, besides the common nutritional properties; they evidently improve the state of health, the immunologic status and decrease the disease risk.
    • Hepatitis C in Romania . The latest research showed that 10 % of Romanian population is diagnosed with this affection, an important specific feature being the preponderance in the territory of a treatment resistant strain. This is an important health problem, the VHC virus being the cause of 64 % of chronic hepatitis and 55,8 % of cirrhosis.
    • The VHC infection develops in time into hepatic chronic disease (over 50 %), among them, 20% - 30 %, developing the hepatic cirrhosis, and 1-5 % hepatocellular carcinoma. To this context, it's being added the silent nature of this disease (astenovegetative and dyspeptic syndrome, non jaundiced forms at over 75 % of the patients), and the fact that it can only be traced through special lab tests. Most of the patients were diagnosed with chronic liver disease only when they took specific VHC lab tests.
    • The creation of a complex and efficient nutraceutical product is necessary because of 100 cases of infested persons, only a quarter will be cured within the first 6 months without needing a treatment, the rest will develop the chronic form of the disease. Those will require a treatment, especially because most of them won't find out in time about the disease and will suffer major hepatic lesions before being diagnosed. The problem still remains distinct regarding the fact that their still doesn't exist a vaccine to prevent the virus infection (such as in case of VHB virus).
up